(Reuters) -Biotech Halozyme Therapeutics believes the new version of Merck’s blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
According to Halozyme, Merck must sign a licensing agreement in order to sell its new version, the report said.
Merck is developing an injectable version of Keytruda, which could protect it from competition when the intravenous version loses exclusivity later in the decade.
Merck and Halozyme did not immediately respond to a Reuters request for comment.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Comments